Other formulations and future considerations for apomorphine for subcutaneous injection therapy

Area of Science:

• Neuroscience
• Pharmacology
• Neurology

Background:

• Apomorphine is a dopamine agonist used in Parkinson's disease management.
• Traditional administration is via intermittent bolus injection.
• Alternative formulations are being explored for improved therapeutic outcomes.

Purpose of the Study:

• To review non-bolus apomorphine administration methods.
• To discuss potential new uses for apomorphine.
• To evaluate the efficacy and side effects of various apomorphine formulations.

Main Methods:

• Review of literature on continuous subcutaneous (sc), intranasal, sublingual, and rectal apomorphine.
• Analysis of reported dosages, onset, duration, and side effects.
• Comparison of different administration routes in Parkinson's disease patients.

Main Results:

• Continuous sc apomorphine (4 mg/h) is well-tolerated, potentially replacing other therapies, but causes skin complications in over 50% of patients.
• Intranasal apomorphine (2-5 mg) offers rapid but short-lived relief (45-55 min), with side effects including nasal irritation and nausea.
• Sublingual apomorphine shows slower onset (40+ min) and causes stomatitis, while rectal administration (200 mg suppository) provides longer duration (195 min) but with sedation and nausea.

Conclusions:

• Non-bolus apomorphine formulations offer alternative therapeutic strategies for Parkinson's disease.
• Each administration route presents distinct efficacy profiles and side effect burdens.
• Apomorphine may also aid in evaluating patient suitability for deep brain stimulation surgery.